Merck Sharp + Dohme Corp.

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Medshine Discovery Inc.

Kpc Pharmaceuticals, Inc.

Dahai Wang

Joseph A Kozlowski

Shilan Liu

Bin Hu

Wensheng Yu

Jian Liu

Bin Zhong

Hao Wu

Craig Alan Coburn

Xiaolei Gao

Deodial Guy Guiadeen

Sobhana Babu Boga

Jiaqiang Cai

Jinglai Hao

Ling Tong

Chundao Yang

Shuhui Chen

Guoping Hu

Brian M Andresen

Guibai Liang

Jian Li

Michael D Altman

Michael P Dwyer

Stuart B Rosenblum

Lei Chen

Younong Yu

Fei Sun

Bandarpalle B Shankar

Wei Wei

Richard Soll

Tony Siu

Rajan Anand

De-Yi Yang

Wenyuan Qian

Kartik M Keertikar

Razia Rizvi

Deyou Sha

Tao Ji

Oleg B Selyutin

Deodialsingh Guiadeen

Jae-Hun Kim

Abdul-Basit Alhassan

Changmao Shen

Honglin Wang

Zhixin Lei

Jyhshing Wang

Shuai Zan

The present invention relates to benzimidazole compounds and an application thereof as IDH1 mutant inhibitors, in particular, to a compound as represented by formula (I), tautomers thereof, or pharmaceutically acceptable salts thereof. 

Benzimidazole derivatives and use thereof as IDH1 inhibitors

The present application relates to a crystal of a tricyclic compound, in particular to a crystal of (S)-8-(4,4-difluorocyclohexyl)-8H-thieno[3,4]pyrrolo[1,5-a]imidazole, a preparation method therefor, a crystal composition and a pharmaceutical composition thereof and the use thereof. The X-ray powder diffraction spectrum of the crystal of the compound of formula I in the present application, represented by a 2&#x3b8; value, has a diffraction peak at about 11.49&#xb0;, 15.05&#xb0;, 20.14&#xb0;, 21.53&#xb0; or 21.79&#xb0;. The crystal of the compound of formula I in the present application has excellent physical properties, high safety and metabolic stability, and has a good inhibitory effect on IDO and a high medicinal value.

Crystal of tricyclic compound

A compound of Formula (I) or (II), for treating or preventing an HCV infection in a subject. 

Hepatitis C virus inhibitors

The present invention relates to novel Chromane-Substituted Tetracyclic Compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein A, A', RR, Rand Rare as defined herein. The present invention also relates to compositions comprising a Chromane-Substituted Tetracyclic Compound, and methods of using the Chromane-Substituted Tetracyclic Compounds for treating or preventing HCV infection in a patient. 

Chromane-substituted tetracyclic compounds and uses thereof for the treatment of viral diseases

The present invention relates to novel Heterocycle-Substituted Tetracyclic Compounds of Formula (I): (I) and pharmaceutically acceptable salts thereof, wherein A, A', RRand Rare as defined herein. The present invention also relates to compositions comprising at least one Heterocycle-Substituted Tetracyclic Compound, and methods of using the Heterocycle-Substituted Tetracyclic Compounds for treating or preventing HCV infection in a patient. 

Heterocycle-substituted tetracyclic compounds and methods of use thereof for the treatment of viral diseases

Provided are compounds of formula I and formula II or pharmaceutically acceptable salts of the compounds and pharmaceutical compositions thereof. The compounds of formula I and formula II or the pharmaceutically acceptable salts of the compounds provide indole 2,3-dioxygenase (IDO) inhibitory activity and are capable of treating IDO-mediated immunosuppressive diseases, such as infectious diseases or cancer. 

Tricyclic compound serving as immunomodulator

The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula (I), or pharmaceutically acceptable salts thereof, wherein X, X, R, R, Rand Rare as herein described. The present invention also provides pharmaceutical compositions comprising these compounds and methods for their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds of Formula (I) in the treatment of Btk mediated disorders. 

Indazole and azaindazole Btk inhibitors

The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula (I), or pharmaceutically acceptable salts thereof, or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds of Formula (I) in the treatment of Btk mediated disorders. 

Btk inhibitors

The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula I, or pharmaceutically acceptable salts thereof, Formula I or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds of Formula I in the treatment of Btk mediated disorders. 

Tertiary alcohol imidazopyrazine BTK inhibitors

Benzamide imidazopyrazine Btk inhibitors

The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula (I), or pharmaceutically acceptable salts thereof, Formula (I) or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds of Formula I in the treatment of Btk mediated disorders. 

Substituted imidazo[1,5-a]pyrazines as Btk inhibitors

The present invention relates to novel Fused Tetracyclic Heterocyclic Compounds of Formula I: (I), wherein A, A', R, R, R, R, R, and Rare defined herein. The compounds and their pharmaceutically acceptable salts are useful for the prophylaxis or treatment of infection by HCV and the prophylaxis, treatment, or delay in the onset of disease caused by HCV. The present invention also relates to pharmaceutical compositions comprising at least one Fused Tetracyclic Heterocyclic Compound, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines, and methods of using the Fused Tetracyclic Heterocyclic Compounds for treating or preventing HCV infection in a patient. 

Fused tetracyclic heterocyclic compounds and methods of use thereof for the treatment of viral diseases

The present invention relates to novel Tetracyclic Xanthene Derivatives of Formula (I) and pharmaceutically acceptable salts thereof, wherein A, Y, Y, Z, R, R, R, Rand Rare as defined herein. The present invention also relates to compositions comprising at least one Tetracyclic Xanthene Derivative, and methods of using the Tetracyclic Xanthene Derivatives for treating or preventing HCV infection in a patient. 

Tetracyclic xanthene derivatives and methods of use thereof for the treatment of viral diseases

Growing community of inventors

Shanghai, China

Dahai Wang